A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group
Author:
Publisher
Elsevier BV
Subject
Oncology
Reference54 articles.
1. Development and use of integral assays in clinical trials;Schilsky;Clin Cancer Res,2012
2. Adapting clinical paradigms to the challenges of cancer clonal evolution;Murugaesu;Am J Pathol,2013
3. Considerations on development, validation, application, and quality control of immuno(metric) biomarker assays in clinical cancer research: an EORTC-NCI working group report;Sweep;Int J Oncol,2003
4. Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development;Poste;Clin Cancer Res,2012
5. Criteria for the use of omics-based predictors in clinical trials;McShane;Nature,2013
Cited by 31 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Future Directions and Challenges in Overcoming Drug Resistance in Cancer;Drug Resistance in Cancer: Mechanisms and Strategies;2024
2. High expression of cytoplasmic FOXO3 protein associated with poor prognosis of rectal cancer patients: A study from Swedish clinical trial of preoperative radiotherapy to big database analysis;Heliyon;2023-05
3. Research governance and compliance management;Clinical Trials and Tribulations;2023
4. The Significance of External Quality Assessment Schemes for Molecular Testing in Clinical Laboratories;Cancers;2022-07-28
5. Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: the pathologists' perspective;Annals of Oncology;2021-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3